Alnylam Pharmaceuticals, Inc. (ALNY)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (“Alnylam”) (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has entered into separate, privately negotiated repurchase agreements with certain holders of its 1.00% Convertible Senior Notes due 2027 (the “Notes”) to repurchase for cash (the “Repurchases”) approximately $34.4 million aggregate principal amount of the Notes for a total repurchase cost (including accrued and unpaid interest) of approxima.

Federated Hermes Inc. increased its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) by 22.6% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 323,842 shares of the biopharmaceutical company's stock after acquiring an additional 59,669 shares during the period.

Alnylam has been a big winner for investors since its IPO in 2004. The drugmaker's future looks promising.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced changes to its Board of Directors, including the departure of two directors and the appointment of a new independent director. Mike Bonney and Carolyn Bertozzi, Ph.D., who have served in key roles on Alnylam's Board, stepped down effective December 2, 2025. Mr. Bonney joined our Board in 2014 and served as Board Chair from December 2015 to August 2021 and as Ex.

Those four companies, culled from a list drawn up by KBW analyst Shreyank Gandhi, are among the largest not in the index.

Google's parent company received a relatively benign antitrust ruling that would not force Alphabet to sell its Chrome browser or Android operating system. Chipotle Mexican Grill reported mixed quarterly results as a result of tough year-over-year comparisons and an uncertain macroeconomic environment. We initiated a position in Oracle, which is highly levered to the ongoing artificial intelligence infrastructure build-out.

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) stock is trading higher on Friday, with no news to justify the movement.

The Virtus Silvant Mid-Cap Growth Fund returned +5.43% (Class INST) for the quarter, compared to the Russell Midcap Growth Index's return of +2.78%. Palantir Technologies (PLTR) and Roblox (RBLX) were among the top stock contributors. Fair Isaac Corp. (FICO) and Verisk Analytics (VRSK) were among the largest stock detractors.

The S&P 500's TJX is among the five stocks to watch showing resilience in a tough market

The UK's drug cost-effectiveness watchdog has recommended Alnylam Pharmaceuticals' heart disease drug, ensuring access for patients through the government health system in England and Wales, the company said on Friday.

Catalyst Funds Management Pty Ltd reduced its position in Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) by 43.9% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 10,770 shares of the biopharmaceutical company's stock after selling 8,430 shares during the quarter. Alnylam Pharmaceuticals comprises about

Alnylam Pharmaceuticals, Inc. ( ALNY ) Jefferies London Healthcare Conference 2025 November 19, 2025 6:30 AM EST Company Participants Yvonne Greenstreet - CEO & Director Tolga Tanguler - Executive VP & Chief Commercial Officer Conference Call Participants Maurice Raycroft - Jefferies LLC, Research Division Presentation Maurice Raycroft Jefferies LLC, Research Division Hi, everyone. My name is Maurice Raycroft, and I'm one of the Biotech Analysts at Jefferies.

Here is how Alnylam Pharmaceuticals (ALNY) and Collegium Pharmaceutical (COLL) have performed compared to their sector so far this year.

Banco Bilbao Vizcaya Argentaria S.A. trimmed its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) by 2.2% in the undefined quarter, according to its most recent disclosure with the SEC. The institutional investor owned 22,251 shares of the biopharmaceutical company's stock after selling 512 shares during the quarter. Banco Bilbao Vizcaya Argentaria

Alnylam Pharmaceuticals boasts an exciting product lineup and pipeline. IonQ could be one of the biggest winners in the fast-growing quantum computing market.

Alnylam Pharmaceuticals, Inc. ( ALNY ) UBS Global Healthcare Conference 2025 November 10, 2025 10:15 AM EST Company Participants Jeffrey Poulton - CFO & Executive VP John Vest - Senior Vice President of Clinical Research Conference Call Participants Ashwani Verma - UBS Investment Bank, Research Division Presentation Ashwani Verma UBS Investment Bank, Research Division All right. Good day, everybody.